Skip to content

Neobiomics AB and BIOS THERAPEUTICS announce an exclusive collaboration for distribution of ProPrems® in Greece

Stockholm July 21, 2023 – Neobiomics and Bios Therapeutics have entered into a
Distribution Agreement under which Bios Therapeutics has the exclusive rights to register, market and sell Neobiomics’ proprietary product ProPrems® in Greece. ProPrems® is a high-quality product for safe food supplementation with one billion bacteria of three well-documented strains – Bifidobacterium infantis, Bifidobacterium lactis and Streptococcus thermophilus.

Dr. Stefan Johansson, CEO and co-founder of Neobiomics AB, says: “We are very happy
to extend our distributor network into Greece. With its niche network, Bios Therapeutics is
the perfect partner for us, with the capacity to make ProPrems® readily available in Greece.”

Michalis Siachos, CEO and founder of Bios Therapeutics, comments: “We are delighted to
work with Neobiomics, an innovative company with an R&D pipeline of products within
neonatal intensive care. This partnership represents a significant addition to our portfolio in
Greece and fits with our strategy to build a strong and niched business.”

Neobiomics looks forward to strengthening our collaboration with Bios Therapeutics in the coming days.

For additional questions/ queries, feel free to reach us at